NYU Study Links GLP-1 Drugs to 7% Higher Hair Loss Risk in Genetically Predisposed Men — NYU Langone Health

Event summary

NYU Langone study finds 7% increased risk of androgenetic alopecia in men using GLP-1 drugs like Ozempic and Wegovy who have genetic predisposition.
Researchers analyzed GLP1R gene activity and its correlation with hair loss genes in over 200,000 mostly White men.
Study controlled for hypertension, insulin resistance, and testosterone levels, with the 7% risk increase remaining consistent.
Findings published in Journal of Investigative Dermatology on September 3, 2026.
Researchers suggest potential for pre-prescription screening and combination treatments to mitigate hair loss risk.

The big picture

This study provides the first genetic evidence linking GLP-1 drugs to increased hair loss risk in predisposed men, potentially influencing prescribing practices and patient counseling. With GLP-1 drug prescriptions having tripled since 2020, this finding could impact a significant portion of the 12% of Americans using these medications primarily for weight loss. The research suggests a biological connection between GLP-1 activity and hair follicle health, opening avenues for targeted interventions.

What we're watching

Regulatory Scrutiny: Whether this study will prompt regulatory bodies to require updated labeling or warnings for GLP-1 drugs regarding hair loss risks.
Market Impact: How pharmaceutical companies may respond with new combination therapies or alternative formulations to address hair loss concerns among GLP-1 users.
Research Expansion: The pace at which researchers will extend this genetic link analysis to women, given the current study's focus on male-pattern hair loss.